Gentian Diagnostics AS Gentian Diagnostics AS

Gentian Diagnostics AS

GENT

Rank in Stocks #21624
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents... Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.
Share Price
$4.16
Last synced: 2026-11-12
Market Cap
$64.37M
Change (1 day)
-0.02%
Change (1 year)
-23.06%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for Gentian Diagnostics AS (GENT)
EPS as of September 2026 TTM: $-0.03
According to Gentian Diagnostics AS's latest financial reports, its current EPS (TTM) is $-0.03. At the end of 2025 the company had an EPS of $0.09, a decrease compared to its 2024 EPS of $0.26.
EPS history for Gentian Diagnostics AS from 2013 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.03 -138.33%
2025 $0.09 -67.12%
2024 $0.26 -482.60%
2023 $-0.07 -57.52%
2022 $-0.16 -12.60%
2021 $-0.18 42.10%
2020 $-0.13 -57.08%
2019 $-0.30 97.62%
2018 $-0.15 15.12%
2017 $-0.13 42.12%
2016 $-0.09 182.32%
2015 $-0.03 -6.02%
2014 $-0.03 -370.54%
2013 $0.01 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$8.45 -24,592.75%
IE
$0.21 -703.77%
CN
$15.05 -43,713.91%
CH
$4.29 -12,529.57%
CH
$0.13 -464.93%
CN

Questions about Gentian Diagnostics AS's earnings per share (EPS)

What is Gentian Diagnostics AS's earnings per share (EPS)?

Gentian Diagnostics AS's earnings per share (EPS) over the last twelve months is $-0.03, as of Sep 2026.

What was Gentian Diagnostics AS's earnings per share (EPS) in 2025?

In 2025, Gentian Diagnostics AS's earnings per share (EPS) was $0.09, 65.38% less than in 2024 ($0.26).

How has Gentian Diagnostics AS's earnings per share (EPS) changed since 2020?

From 2020 to 2025, Gentian Diagnostics AS's earnings per share (EPS) was highest in 2024 ($0.26) and lowest in 2021 ($-0.18).

How does Gentian Diagnostics AS's earnings per share (EPS) compare with similar companies?

Gentian Diagnostics AS's earnings per share (EPS) ($-0.03) is lower than that of all 5 similar companies listed above. The highest among them is Ypsomed Holding AG, with $15.05.